Northern Ireland technology and services provider sees revenue increase to £23.7million

Watch more of our videos on Shots! 
and live on Freeview channel 276
Visit Shots! now
Diaceutics has increased revenue by more than 20% in what its chief executive described as ‘another year of strong performance and growth'

Diaceutics, a Belfast-based technology and services provider to the pharma and biotech industry, has increased revenue by more than 20% in what its chief executive described as ‘another year of strong performance and growth’.

Despite challenges in the wider pharma industry, revenue at Diaceutics climbed by 22% to £23.7m in the year to December 31 2023, with 52% of revenues now said to be recurring.

Hide Ad
Hide Ad

Order book value at December 31 2023 stood at £26.5m, Diaceutics added, up from £16.9m, and including £12.3m which will be realised in the current financial year.

Diaceutics, a Belfast-based technology and services provider to the pharma and biotech industry, has increased revenue by more than 20% in what its chief executive described as ‘another year of strong performance and growth’Diaceutics, a Belfast-based technology and services provider to the pharma and biotech industry, has increased revenue by more than 20% in what its chief executive described as ‘another year of strong performance and growth’
Diaceutics, a Belfast-based technology and services provider to the pharma and biotech industry, has increased revenue by more than 20% in what its chief executive described as ‘another year of strong performance and growth’

Adjusted EBITDA for the period slowed from £3.6m to £2.4m while Diaceutics also made a loss before tax of £2.4m.

Read More
Start-up boom as businesses launched in Northern Ireland near triple in April

Chief executive Ryan Keeling, said: "2023 was another year of strong performance and growth for Diaceutics despite it being a challenging year for the wider pharma industry.

"This growth demonstrates the significant value our customers place on our differentiated offering, as reflected by the increasing number of precision medicines we are working with.

"The good momentum we enjoyed in 2023 has continued into 2024 to date and we see many opportunities for growth both with existing and potential new customers."

Comment Guidelines

National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.